These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. SMART? Time will tell. Nat Rev Cancer; 2002 Nov; 2(11):812. PubMed ID: 12442760 [No Abstract] [Full Text] [Related]
27. New treatment, new hope for those with multiple sclerosis. Bren L FDA Consum; 2005; 39(2):10-7. PubMed ID: 16121419 [No Abstract] [Full Text] [Related]
28. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. Mease PJ J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733 [TBL] [Abstract][Full Text] [Related]
29. MRI as an outcome in multiple sclerosis clinical trials. Sormani MP; Filippi M; De Stefano N; ; Ebers G; Daumer M Neurology; 2009 Dec; 73(22):1932; author reply 1932-3. PubMed ID: 19949043 [No Abstract] [Full Text] [Related]
30. [Targeting B cells in multiple sclerosis. Current concepts and strategies]. Menge T; Büdingen HC; Dalakas MC; Kieseier BC; Hartung HP Nervenarzt; 2009 Feb; 80(2):190-8. PubMed ID: 19189075 [TBL] [Abstract][Full Text] [Related]
31. Progress in Multiple Sclerosis Research: An Example of Bedside to Bench. Hauser SL JAMA; 2020 Sep; 324(9):841-842. PubMed ID: 32379266 [No Abstract] [Full Text] [Related]
32. Multiple sclerosis treatment: current best practice. Niino M Expert Rev Clin Immunol; 2012 Aug; 8(6):505-7. PubMed ID: 22992142 [No Abstract] [Full Text] [Related]
33. Therapeutic potential for B-cell modulation in Sjögren's syndrome. Mariette X Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420 [TBL] [Abstract][Full Text] [Related]
34. Daclizumab treatment for multiple sclerosis. Kim SE Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591 [TBL] [Abstract][Full Text] [Related]
35. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Hutas G Curr Opin Investig Drugs; 2008 Nov; 9(11):1206-15. PubMed ID: 18951300 [TBL] [Abstract][Full Text] [Related]
36. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224 [TBL] [Abstract][Full Text] [Related]
37. Neutralizing antibodies to biological therapies: A "touch of gray" vs a "black and white" story. Freedman MS; Pachner AR Neurology; 2007 Oct; 69(14):1386-7. PubMed ID: 17909150 [No Abstract] [Full Text] [Related]
38. The role of B cells in multiple sclerosis: implications for B-cell-targeted therapy. Hirotani M; Niino M; Sasaki H Curr Med Chem; 2010; 17(28):3215-22. PubMed ID: 20666723 [TBL] [Abstract][Full Text] [Related]
39. Identification and development of new therapeutics for multiple sclerosis. Linker RA; Kieseier BC; Gold R Trends Pharmacol Sci; 2008 Nov; 29(11):558-65. PubMed ID: 18804288 [TBL] [Abstract][Full Text] [Related]
40. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis. Darlington C Curr Opin Mol Ther; 2007 Aug; 9(4):398-402. PubMed ID: 17694453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]